Evidence map›Paper›PMID 37023136›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

LPS-aggregating proteins GBP1 and GBP2 are each sufficient to enhance caspase-4 activation both in cellulo and in vitro.

Mary S Dickinson, Miriam Kutsch, Linda Sistemich, Dulcemaria Hernandez, Anthony S Piro, David Needham, Cammie F Lesser, Christian Herrmann, Jörn Coers

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. An overview of human inflammasomes: Activation and regulation.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. TheeLife · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. ThebioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mary S DickinsonDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710.ORCID 0000-0002-7227-9640
Miriam KutschDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710.ORCID 0000-0002-9346-2196
Linda SistemichDepartment of Physical Chemistry I, Ruhr-University Bochum, 44801 Bochum, Germany.ORCID 0000-0001-6465-866X
Dulcemaria HernandezDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710.
Anthony S PiroDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710.
David NeedhamDepartment of Mechanical Engineering and Material Science, Duke University, Durham, NC 27708.ORCID 0000-0002-0082-9148
Cammie F LesserCenter for Bacterial Pathogenesis, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02139.ORCID 0000-0002-1702-6333
Christian HerrmannDepartment of Physical Chemistry I, Ruhr-University Bochum, 44801 Bochum, Germany.ORCID 0000-0002-1824-3647
Jörn CoersDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710.ORCID 0000-0001-8707-4608
Duke Medical Center · USRuhr University Bochum · DEDuke University · USHarvard University · US

Funding

Modeling mechanisms of Shigella pathogenesis in yeastR01AI064285 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LESSER, CAMMIE · 2006 to 2017
$4.0M
Interferon-inducible cell-autonomous immunity to cytosolic bacterial pathogensR01AI139425 · NIAID · DUKE UNIVERSITY · PI Jorn Coers · 2019 to 2026
$3.4M
Shigella mediated regulation of epithelial cell inflammasomesR01AI169795 · NIAID · TUFTS UNIVERSITY BOSTON · PI CAMMIE LESSER · 2023 to 2026
$3.0M
IRGM proteins as regulators of inflammationR01AI148243 · NIAID · DUKE UNIVERSITY · PI COERS, JOERN, TAYLOR, GREGORY A · 2020 to 2024
$2.4M
NIAID NIH HHS R01 AI064285NIAID NIH HHS R01 AI139425NIAID NIH HHS R01 AI148243NIAID NIH HHS R01 AI169795
6 · The paper itself

Abstract

The gamma-interferon (IFNγ)-inducible guanylate-binding proteins (GBPs) promote host defense against gram-negative cytosolic bacteria in part through the induction of an inflammatory cell death pathway called pyroptosis. To activate pyroptosis, GBPs facilitate sensing of the gram-negative bacterial outer membrane component lipopolysaccharide (LPS) by the noncanonical caspase-4 inflammasome. There are seven human GBP paralogs, and it is unclear how each GBP contributes to LPS sensing and pyroptosis induction. GBP1 forms a multimeric microcapsule on the surface of cytosolic bacteria through direct interactions with LPS. The GBP1 microcapsule recruits caspase-4 to bacteria, a process deemed essential for caspase-4 activation. In contrast to GBP1, closely related paralog GBP2 is unable to bind bacteria on its own but requires GBP1 for direct bacterial binding. Unexpectedly, we find that GBP2 overexpression can restore gram-negative-induced pyroptosis in GBP1

Indexed as

GTP-Binding ProteinsLipopolysaccharidesCapsulesCarrier ProteinsCaspases, InitiatorHumansInflammasomesInterferon-gammaPyroptosisCapsulesCarrier ProteinsCaspases, InitiatorGBP1 protein, humanGBP2 protein, humanGTP-Binding ProteinsInflammasomesInterferon-gammaLipopolysaccharidescell-autonomous immunityguanylate-binding proteinsinflammasomeinterferon-stimulated geneslipopolysaccharide

Identifiers

PMID37023136
PMCPMC10104521
OpenAlexW4362658169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.